When will qelbree be generic?

Qelbree Patent Expiration Date

Qelbree, also known as viloxazine extended-release, is an oral medication for the treatment of adult attention deficit hyperactivity disorder (ADHD) and major depressive disorder (MDD) [1]. According to DrugPatentWatch.com [2], the patent for Qelbree (viloxazine extended-release) is expected to expire in 2038.

Generic Versions

Generic versions of Qelbree will become available after the patent has expired. Manufacturers may begin developing generic versions of the medication, which could lead to increased competition and potentially lower prices [3].

Timeline and Availability

As the patent approaches its expiration date, pharmaceutical companies will begin to develop and market generic versions of Qelbree. It is possible that generic versions may become available before the patent officially expires, especially if there are multiple patent challenges or settlements.

Exclusivity Period

Once generic versions of Qelbree become available, they will enter the market during the exclusivity period for the original drug. This period lasts for six months, after which multiple generic versions can be marketed simultaneously [4].

Regulatory Approvals

Generic versions of Qelbree must undergo regulatory review and approval by the Food and Drug Administration (FDA) before they can be marketed. It is likely that several companies will pursue regulatory approvals for their generic versions of the medication, leading to a surge in availability once the patent expires.

Sources:

[1] Qelbree (viloxazine extended-release) on the FDA website
[2] DrugPatentWatch.com: Viloxazine extended-release patent information
[3] Competitive pricing for generic medications on DrugPatentWatch.com
[4] FDA regulations on exclusivity period for branded and generic medications